Promis Neurosciences Inc., of Toronto, said it identified a second distinct epitope on misfolded strains of amyloid beta and acquired an exclusive global license to the Alzheimer's disease (AD) target through an expanded license agreement with the University of British Columbia. The company also submitted a provisional patent application for the target to the U.S. Patent and Trademark Office.